This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer - supporting Jaguar's strategy to secure non-dilutive partnership funding

Kanawha Medical expands access to Olympus endoscopes with trusted models, affordable pricing, and expert after-sale support.

"Collectors brace for a bidding showdown as Michael Jordan's iconic game-used gear surfaces online."

Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.

Acquisition Will Enhance ClearPoint Neuro's Commercial Scale, Drive Operational Leverage, and Support Its Long-Term Strategy in CNS Drug Delivery Innovation

CEO's personal open-market investment reflects long-term alignment with shareholders and continued commitment to transparency, excellence and innovation.

• Conformity with stringent new EU regulations for medical devices confirmed

• Allows for commercialization of Bentrio in EU member states; facilitates regulatory approval in various other countries

• Major milestone in international growth strategy

The best rhinoplasty in Seattle is by Dr. Sajan

Crofelemer can potentially extend lives of MVID patients - infants and children who face the lethal natural history of the disease

Parenteral support reduction of up to 37% is groundbreaking; No approved treatments exist for MVID in any region

~ FDA Response Streamlines Path to Commercial Production of PF614~

Non-dilutive financing from premier lender bolsters strong balance sheet and provides increased flexibility

Company reiterates 2025 financial guidance provided on 3Q25 earnings call and targets cash breakeven by 2028

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026

Expects to expand seasonal vaccine franchise from three to up to six approved products by 2028

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene

Further improves 2026 and 2027 expected GAAP operating expenses by approximately $0.5 billion each year on path to targeted cash breakeven in 2028

No Reserve | Auction Ends Tonight, Thursday, November 20, 2025

Honored for Delivering Exceptional Primary Care to the Morongo Basin Community

James Huang appointed as Non-Executive Chairman of CASI Board of Directors

Brought to you by Bionic Bloom collection of wellness.

New capabilities strengthen U.S. production, completing Moderna's domestic end-to-end mRNA manufacturing network

More than $140 million investment will create hundreds of highly skilled biomanufacturing jobs

With the global pain-management market projected to surpass $93.9 billion by 2030 and topical analgesics growing at a 7.2% CAGR, CBDL positions itself for major East Coast expansion amid surging consumer demand for natural relief solutions.

It is with the greatest of sadness and the deepest of regret that Compassion Center announces the passing of its most beloved, precious, fearless, and courageous leader, Julie "Nurse Juhlzie" Monteiro (Creel), who peacefully transitioned of natural causes on November 11th, 2025, in the comfort, warmth, and sanctuary of her cozy king-sized bed.

Dr. Mohammed brings advanced training in wound care, sports injuries, and reconstructive foot and ankle surgery to two key metro Atlanta locations.

Study to Deliver Insulin to Internal Testers Wearing Continuous Glucose Monitors

Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership

~Funding supports Phase 3 clinical development of PF614 and continued innovation in abuse- and overdose-resistant analgesics~

Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion disease (MVID), reducing the volume of the total parenteral support (PS) necessary for them to survive, though with associated toxicity; Groundbreaking PS reduction of up to 37%; No approved treatments exist for MVID

Company completed meeting with FDA October 2, 2025 for advice on possible expedited approval pathway to advance its ongoing placebo-controlled trial of crofelemer for potential approval for treatment of MVID

SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access, affordability, domestic manufacturing and rare-disease alignment.

Clinical development programs for doxorubicin-containing microneedle array (D-MNA) and Teverelix, a next generation GnRH antagonist, are steadily advancing

~ Third Quarter Highlighted by Initiation of Phase 3 Study of PF614, Underscoring Progress Toward Market Readiness and Commitment to Novel Opioid Solutions ~

~ Further Program Advancement Supported by Preferred Stock Financing ~

- Dermata announced a strategic pivot to develop and commercialize over-the-counter (OTC) skin care treatments -

- Dermata plans to launch its first OTC product, a once weekly acne kit with its Spongilla technology, in the middle of 2026 -

With 6-figure expectations this one of one 2009 Topps Unique Tom Brady card featuring a game-worn NFL Equipment patch and autograph is now live at Fanatics Collect's Premier Auction that ends Thursday, November 20, 2025 at 9:30 PM Eastern Time (EST).

-Targets $3 Billion "Almost-Pumper" Market with First Simplified and Removable/Replaceable Insulin Patch Pump

- Aims to Improve Patient and Clinician Experience for the Care of Diabetes

Quarterly Results Reflect First Full Quarter Including Wattbike (Acquisition Closed July 1)

Company Reports Record Quarterly Revenue of $4.8 Million; Net Loss and Loss per Diluted Share of $5.2 Million and $3.11; Quarterly Adjusted EBITDA Loss of $2.9 million, Due to Low Inventory Availability

Sportstech Acquisition Expected to Close in 2025 Based on Key Closing Milestone Achievements

Reiterates 2025 Pro Forma Revenue Guidance of more than $80 million and Fourth Quarter Profitability Guidance

Outdoor toy-drive event rescheduled to prioritize safety as Las Vegas faces 70-90% chance of rain on Saturday

Total net revenue of $13.9 million

Net income of $2.0 million, or $0.21 net income per share basic

Adjusted EBITDA¹ of $(0.6) million, which includes EXXUA launch investments

$32.6 million cash balance at September 30, 2025

Company remains on track to launch EXXUA™ (gepirone) extended-release tablets ("EXXUA") in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market

Company to host conference call and webcast today, November 13, 2025, at 4:30 p.m. Eastern time

Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to survive

Groundbreaking PS reduction of up to 37% is unprecedented; No approved treatments exist for MVID

Timed with a sharp acceleration in AI-data-center expansion, with more than $60B in new projects announced in the last 90 days.

THE SKNJCT-003 CLINICAL STUDY EXPANSION INTO THE UNITED KINGDOM TO FURTHER ENABLE GLOBAL PATIENT RECRUITMENT AND CLINICAL DATASET TOWARD A PIVOTAL STUDY PROGRAM